Industry Spotlight: Medical Devices

Evan D. Poff
Brigham Young University, evan.poff@byu.net

Follow this and additional works at: https://scholarsarchive.byu.edu/marriottstudentreview

Part of the Alternative and Complementary Medicine Commons, Biotechnology Commons, Business Administration, Management, and Operations Commons, Equipment and Supplies Commons, Insurance Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Other Business Commons, Other Medicine and Health Sciences Commons, and the Technology and Innovation Commons

Marriott Student Review is a student journal created and published as a project for the Writing for Business Communications course at Brigham Young University (BYU). The views expressed in Marriott Student Review are not necessarily endorsed by BYU or The Church of Jesus Christ of Latter-day Saints.

Recommended Citation
Poff, Evan D. () "Industry Spotlight: Medical Devices," Marriott Student Review: Vol. 2 : Iss. 3 , Article 12. Available at: https://scholarsarchive.byu.edu/marriottstudentreview/vol2/iss3/12

This Recurring Feature is brought to you for free and open access by the All Journals at BYU ScholarsArchive. It has been accepted for inclusion in Marriott Student Review by an authorized editor of BYU ScholarsArchive. For more information, please contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.
Amid the gamut of human ailments and frailties plaguing the world today, medical devices restore and even redefine health. The medical device industry comprises wide varieties of technologies that repair life and augment living. These range from internal pacemakers to external defibrillators, from full-size wheelchairs to small dental implants, and from individualized knee replacements to institution-wide MRI machines. Indeed, the scope of needs both general and specific supplies an instrumental strength to these companies.

Though mortal existence itself would seem to suggest industry stability, the unavoidable nature of illness and injury alone does not guarantee success. In the United States, any aspiring medical device must first clear regulated protocol—mandatory whenever introducing medical devices to the American market or significantly modifying them. This approvals process can be relatively straightforward for simple devices with well-established precedents. A good example of this is bandages, which primarily require only appropriate labeling, registration, and quality standards. However, application stringency quickly rises as devices become more intricately and tightly entwined with our lives. The higher the potential of “risk” a medical device has, the more stipulations are attached. These terms can include the FDA reviewing preliminary clinical data (which itself requires prior approval) before granting pre-market approval or conducting post-market patient surveillance to ensure acceptable outcomes. Specification developers, manufacturers, and exporters are also covered by these procedures, whether they see the device through from start to finish, create replacement parts, or only design products for others to build. Even re-packagers must adhere to these laws (How to Study and Market Your Device).

Once in the market, entrants must deal with a new array of obstacles. This can be as fundamental as how a product can be sold. While our simple example of bandages once again gets an easy, comfortable spot on store shelves everywhere, where do you buy a prosthetic? Which aisle in your local supermarket or even a specialty shop would have implants? In the United States at least, the reality is that many of these medical devices only come to patients by way of medical centers and clinics. That also means insurance. Figuring out how to price and distribute products when people have to go through third parties to get them becomes a critical part of the business model, which is far from a traditional, commercial approach. Managing obstacles like these requires adopting a paradigm different than what many business professionals and students may be used to, but once embraced, the proper mindset sets the stage for navigating this industry’s unique challenges.

Successful providers of healthcare solutions fare financially well. Total revenue for the global medical technology market last year was valued at US$405 billion (Evaluate, Global Medtech Revenue), over half of which comes from USA companies (EY, Total Revenues). Chunks to the tune of US$24 billion are passed around for acquisitions like BD’s (Becton, Dickinson and Company) of C.R. Bard, Inc. (EY, Major Medtech M&A). The numbers are rising. In 2017, medtech R&D spending experienced 4.7 percent growth worldwide (Evaluate, R&D Spending Growth), an expenditure equivalent to 7.1 percent of these companies’ total revenues (Evaluate, R&D as Percent of Revenue) and which is expected to reach US$30 billion.

Companies may take the strategy of postponing any patent application... to keep those rights of exclusivity for that much longer.
this year (Evaluate, R&D Spending). The top two medical technology companies in the world are Medtronic, Inc., and the Medical Devices & Diagnostics segment of Johnson & Johnson (ProClinical), both based in the US and projected to generate revenues of US$38.9 and US$33.4 billion respectively (Evaluate, Projected Top 10).

Some may wonder whether these large revenues might house hefty profit margins. Remember, though, that such quantities of capital allow for financial security in the face of recalls and lawsuits at worst and for continued R&D at best. Under more typical conditions, a company files a patent to secure the best possible chance for making profits, but all the time spent getting the device approved by the proper agencies whittles away at that short window of opportunity. Assuming there are no problems with the other aspects of commercialization, what may start out as a nominal twenty-year USA patent may drop to only sixteen or ten years of usable time on the market if the innovation is particularly novel (Morton). In such circumstances, companies may take the strategy of postponing any patent application until after a few years of development have proven successful, in effect betting that no one else will file for a similar patent before them in order to keep those rights of exclusivity for that much longer. Looking at the entire process, getting before them in order to keep those rights of exclusivity for that much longer. Looking at the entire process, getting

Notwithstanding these new frontiers, the true future of the medical devices industry revolves around people, not technologies. Instead of becoming “the go-to” by amassing a portfolio of top-notch solutions to disparate healthcare problems, the value that medical device suppliers now strive for is a unified, patient-centric experience. Healthcare is no longer a game of getting hospitals and clinics the best devices at the best prices. Rather, success in the field has everything to do with how informed and in-control your typical customer feels. Michael Brown, VP of National Healthcare Systems at Agfa HealthCare, described this distinction while speaking with the peer-reviewed publication Medical Device and Diagnostic Industry: “The conversation needs to change away from price and into outcomes... Patient information [should talk to one another] in one common area” (Kane). The implications of such an approach are especially critical for those involved in these companies’ business decisions. After all, this “value-based” business model is about establishing user-beneficial systems of interconnected services, not star products.

The destiny of the medical device industry lies not in inventing innovations, but rather in integrating them. In creating holistic profiles and interfacing separate devices’ observations into one, perhaps the industry will also bring us, each other, and technology naturally into a healthier symbiosis.

HEALTHCARE IS NO LONGER A GAME OF GETTING HOSPITALS AND CLINICS THE BEST DEVICES AT THE BEST PRICES.